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A grande limitação do uso de fármacos citotóxicos em terapias antitumorais 
resume-se à falta de capacidade destas moléculas em distinguir células tumorais e 
células saudáveis. Os Tumor Targeting Peptides (TTPs), desde a sua descoberta há 
30 anos atrás, têm-se tornado numa ferramenta útil para o tratamento e diagnóstico do 
cancro, uma vez que reconhecem alvos moleculares tumorais específicos, tal como os 
anticorpos (Abs), mas sem as suas desvantagens estruturais. Assim, a sua utilização 
no desenvolvimento de conjugados terapêuticos peptídicos (PDCs) é bastante 
promissora, embora ainda nenhum destes sistemas de entrega de fármacos esteja 
aprovado para uso clínico.  
O objetivo deste trabalho consistiu na revisão de literatura relacionada com 
abordagens terapêuticas alvo-dirigidas e na organização e resumo dos TTPs que 
contribuíram de uma forma mais valiosa para os avanços no desenvolvimento de 
conjugados terapêuticos.  
Neste trabalho, foram apresentados 9 péptidos com capacidade de 
reconhecimento alvo-específico, representativos de cada classe de TTPs e 
promissores quanto a uma futura aplicação clínica como parte integrante de 
conjugados terapêuticos - RGD, NGR, F3, Octreotide, LyP-1, Bombesin, Angiopep 2, 
CREKA e M2pep. Desta forma, foram focados para cada um dos TTPs, pontos-chave 
relativos a características estruturais e funcionais, alvos celulares específicos, estudos 
de relação estrutura-atividade (SAR), capacidade de internalização e aplicações no 
desenvolvimento de conjugados terapêuticos. 
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 The major inconvenient of the use of cytotoxic drugs in anti-tumor therapies is 
their poor ability to distinguish tumor cells from the normal cells. Since their discovery 
about 30 years ago, tumor targeting peptides (TTPs) have become an useful tool for 
the treatment and diagnosis of cancer, once they are able to recognize specific tumor 
targets, such as antibodies (Abs) but without their structural disadvantages. Thus, their 
use in the development of peptide-drug conjugates (PDCs) is promising, although none 
of these drug delivery systems (DDS) are approved for clinical use yet. 
 The aim of this work was to review the literature about tumor targeting 
approaches and to organize and summarize the TTPs that contributed in a significant 
way to the advances of this field, including the development of therapeutic conjugates.  
 In this work, nine peptides with targeting ability, representative of each class of 
TTPs and promising for a future clinical application as an integral part of drug 
conjugates were presented - RGD, NGR, F3, Octreotide, LyP-1, Bombesin, Angiopep 
2, CREKA and M2pep. This way, structural and functional features, addresses, 
structure-activity relationship (SAR) studies, internalization capacity and applications in 
the development of therapeutic conjugates were focused as key-points for each 
targeting peptide. 
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Cancer is characterized by the uncontrolled growth of abnormal cells due to 
mutations of genes involved in cells growth, proliferation or survival, creating a complex 
chain of events and modifying basic biological operations of cells, such as the ability to 
respond to growth signals, invade tissues and regulate cell death programs. Genetic 
alterations may be inherited or accrued after birth, causing activation of oncogenes or 
inhibition or deletion of tumor suppressor genes.1–4 Cancer cells can evolve to benign 
or malignant tumors. Whereas benign tumors are encapsulated and do not invade 
surrounding tissue, malignant tumors have less well differentiated cells, grow more 
rapidly and invade and destroy adjacent normal tissue, being able to generate 
secondary tumors (metastases) in distant organs in the body through blood vessels 
and lymphatic channels.  
Tumor cells are capable to grow even in the face of starvation of the host, 
causing morbidity or his death. The most common effects on patients are cachexia, 
hemorrhage and infection. In most cases, the origin of the cancer is not clear, but it is 
known that external (such as cigarette smoking and radiation) and internal (like 
immune system defects, genetic predisposition) factors can contribute to cancer 
development.1 Current cancer treatments are surgery, radiation and chemotherapy.2,5 
Whereas surgery allows the removal of solid tumors (in other words, tumors confined to 
the anatomical area of origin or primary tumors), radiation therapy is based on the 
biological effect of ionizing radiations in tumor localization. Moreover, chemotherapy, 
the basis for the treatment of disseminated tumor, uses chemicals with cytotoxic 
properties.3,6–8 Although classical chemotherapy assumes that cytotoxic drugs target 
the faster proliferating tumor cells, they still interfere with normal cells, inducing 
systemic toxicity and causing severe secondary effects like nausea, vomiting, hail loss, 
damages to liver, bone marrow and kidney.9    
Over the past two decades, it was verified a continuous decline in number of 
deaths by cancer in consequence of significant advances in the development of 
anticancer drugs.10,11  Still, cancer remains one of the leading cause of death 
worldwide, with metastases being the major complication in patients with cancer.1,10–13 
Besides, generalized anatomic imaging techniques has lack of sensitivity to provide 
early diagnosis for cancer.12 
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1.1. Tumor Microenvironment 
In primary tumors, cancer cells are surrounded by a complex microenvironment 
with unique physicochemical properties, since the fast tumor growth demands a higher 
consumption of energy and oxygen, leading to secondary acidic metabolites 
accumulation, hypoxia and hyperthermia (Figure 1). Here, the most abundant cells type 
is cancer-associated fibroblasts that contribute to extracellular matrix remodeling and 
cellular growth. Moreover, the predominant inflammatory cells, called tumor-associated 
macrophages (TAMs), can differentiate into M2-like macrophages, endowed with 
immunosuppressive features. Other types of cells are encountered in tumor 
microenvironment, including endothelial cells and their precursors, granulocytes, 
lymphocytes, natural killer cells and antigen-presenting cells, like dendritic cells. 
Interactions between tumor cells and their surrounding cells stimulates tumor 
development by production of enzymes, cytokines, chemokines and growth factors, 
angiogenesis occurring, immune escape and extracellular matrix disarrangement.2,14,15 
 
Figure 1: Tumor microenvironment constitutes. Adapted.
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1.1.1. Plasma Membrane 
The plasma membrane has a crucial role in cell’s behavior, namely in 
communication with other cells, cell movement, migration and adherence to other cells 
or structures, access to nutrients in the microenvironment and recognition by the 
body’s immune system. On the plasma membrane of malignant cells, a number of 
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biochemical changes are verified, mainly the appearance of new surface antigens, 
proteoglycans, glycolipids and mucins, and alteration of cell to cell or cell to 
extracellular matrix communication. These changes induce loss of density-dependent 
inhibition of growth, decrease of adhesiveness and loss of anchorage dependence.1,2  
In cancer cells membrane, there is an increased negative charge due to loss of 
symmetry between zwitterionic phospholipids and the consequent exposure of anionic 
phosphatidylserine in the external surface of the plasma membrane. On the other 
hand, the presence of linked sialic acid and glycolipids or glycoproteins like mucins, 
proteoglycans, heparin sulfate and chondroitin sulfate also contributes to increase the 
negative charge of tumor cell membranes.1  
1.1.2. Tumor Vasculature 
Angiogenesis consists in the formation of new blood vessels from pre-existing 
ones, that normally occurs in inflammations or tissues regeneration processes, such as 
tissue growth, wound healing, menstrual cycle and placental implantation.2,16 In solid 
tumors with 1-2 mm or more in diameter, pathological angiogenesis occurs, not only to 
increase supply nutrients and oxygen, but also to carry tumor cells to adjacent and/or 
distant organs.1,11–13,16 In this case, angiogenesis is triggered by hypoxia that activates 
endothelial cells through cell surface and secreted proteins, mostly integrins and matrix 
metalloproteinases, leading to the formation of malformed and dysfunctional new blood 
vessels.15  
Tumor blood vessels exhibit structural and morphological differences from the 
normal vascular system.14 The vasculature in the majority of healthy tissues has a pore 
size of 2 nm and more specifically, post-capillary venules have 6 nm of pore, while in 
the tortuous tumor blood vessels, pores vary in size from 100 to 780 nm.17 In addition, 
solid tumors have poor blood flow through their vessels, but the presence of the 
enhanced permeability and retention (EPR) effect (an alteration in fluid dynamics due 
to the rapid growing and the abnormal tumor neo-vasculature) makes the tumor 
vasculature leaky and porous, enabling cellular metabolites accumulation at higher 
concentration than in normal tissues.2,14 Moreover, tumor endothelial cells express a 
different set of molecules on their surface, that can be angiogenesis-related (like the 
vascular endothelial growth factor (VEGF), heparin sulfate and nucleolin) or tumor 
type-specific.12,14,16,18 
Up to now, very little is known about tumor lymphatic vasculature. In normal 
tissues, lymphatic vessels are responsible for interstitial fluid and macromolecules 
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transportation from tissues to the bloodstream, in a unidirectional way. Thus, like in 
tumor blood vessels, tumor lymphatic vessels may connect to healthy vasculature and 
allow metastases spread.18 
1.2. Tumor Targeting Therapy 
The major inconvenient of cytotoxic drugs are their poor ability to distinguish 
cancer cells from the normal ones.2,11 Particularities of tumor cells, as well of tumor 
microenvironment (increased negative charge of cell membranes, lack of lymphatic 
drainage from the tumor and EPR effect) provides the delivery and uptake of antitumor 
drugs.2,17 In this case, the selectivity to tumor cells is based on a passive targeting 
mechanism, since there is a selective extravasation and accumulation of molecules in 
tumor tissues.17 However, it is common for antitumor drug formulations to have poor 
efficacy due to fail of tumor specificity, insufficient drug accumulation inside the tumor 
microenvironment and drug resistance (in other words, inactivation of the drug in vivo 
or modification of drug targets or drug efflux, through genetic and epigenetic 
modifications of tumor cells) that leads to unwanted side effects, therapeutic failure or 
cancer recurrence.2,3 
Tumor cells and tumor-associated tissues express different or overexpress 
surface antigens or receptors (tissue specific markers also known as vascular bed-
specific zip codes or addresses) compared to normal tissue, which makes them into 
molecular targets to deliver  antitumor molecules through an active targeting 
mechanism (manly known as tumor targeting approach), based on conjugation of 
addresses with their respective high affinity ligands (or tumor targeting molecules).1,2,19 
Surface receptors like integrins, vascular epidermal growth factor (VEGF), folate, 
transferrin, luteinizing hormone-releasing hormone (LHRH), and somatostatin (SST) 
have shown high potential in tumor targeting therapy.14  
1.2.1. Antibodies 
Antibodies (Abs) are the natural targeting proteins of the organism. 
Consequently, Abs or their fragments are the most common targeting molecules 
employed in the delivery of antitumor drugs and imaging agents, since they provide 
antigen-specific binding affinity and can stimulate the immune system to fight or inhibit 
tumor growth.4,14,20 At clinical practice, Abs are utilized as an integral part of antibody-
drug conjugates (ADCs) for cancer therapy, like Trastuzumab and Cetuximab, for 
breast cancer, and colorectal and head and neck cancer, respectively (Figure 2B and 
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C).12,14 Others ADCs, have been approved for radionuclides delivery, immunotoxins 
and antitumor antibiotics.  
It is presently accepted that angiogenesis is the most limiting factor to tumor 
growth, since the loss of blood vessels leads to tumor shrinkage. Thus, it was 
promoted the development of conjugates with the ability to target tumor endothelial 
cells, ADCs or antibody-fusion proteins, like Avastin (bevacizumab) and VEGF-Trap, 
respectively.14 
 




Despite many decades of research, tumor targeting therapy did not reach 
significant clinical success. Abs and large protein ligands have several limitations, such 
as the low tumor tissue penetration ability because of their large size and dose-limiting 
toxicity to the liver, spleen and bone marrow, due to non-specific uptake into the 
reticule-endothelial system. Besides, Abs have a difficult and expensive commercial-
scale production and there is the possibility of anti-idiotypic Abs generation and the 
forming of immune complexes.14 
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In an attempt to counter these disadvantages, there were developed small 
molecules inhibitors (SMIs). SMIs can specifically target tumor addresses in order to 
block cellular pathways or mutant proteins required for cancer cell growth and 
survival.3,25 Today, a lot of SMIs are under pre-clinical and clinical trials, being tyrosine 
kinase inhibitors group the most approved for tumor therapy, such as imatinib, 
sorafenib, erlotinib and lapatinib (Figure 3).3,25,26 
 
Figure 3: Chemical structures of SMIs examples. Adapted.
27
  
1.3. Peptides in Cancer Therapy  
Peptides consist in small proteins, constituted by 50-100 amino acids (Table 1). 
Like proteins, peptides can organize structurally in a primary structure composed by an 
amino acids sequence and in a secondary structure with a special arrangement, like α 
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In cancer therapy, peptides are functional domains of proteins with specific 
bioactivities, including binding to receptors, structural sensitivity to chemical conditions 
(like acidity and temperature), penetration of the plasma membrane and activation or 
inhibition of cellular pathways.2,5 Taking into account anti-tumor therapy, there are three 
main groups of peptides with increased value: antimicrobial peptides or pore-forming 
peptides (AMPs), cell penetrating peptides (CCPs) and tumor targeting peptides 
(TTPs) (Figure 4).15 
 
Figure 4: Classes of peptides with advantageous features in cancer therapy and respective examples. A) 
AMPs B) CPPs; C) TTPs. TAT - trans-activating transcriptional activator.Taken from 
2  
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AMPs (also called host defense peptides or cationic antimicrobial peptides) are 
cytotoxic agents based in naturally occurring peptides of protective innate immune 
response to microbes in many species. This peptides has a cationic amphipathic 
structure that allows them to interact with anionic lipid membranes and induce pores 
formation or membranes disruption, causing cellular necrosis or apoptosis. Whereas 
necrosis is the result of AMPs targeting lipids membrane, leading to cells lysis, 
apoptosis is triggered by mitochondrial membrane disruption. AMPs constitute 
alternative anti-tumor drugs since their cytotoxicity occurs within minutes, decreasing 
drug resistance.2 
On the other hand, CPPs have the ability to deliver cargos into cells, from small 
molecules to large microparticles, without having tumor cell specificity. CPPs are able 
to penetrate cell membranes directly through the plasma membrane or through several 
internalization mechanisms, such as clathrin- or caveolin-mediated endocytic pathway, 
micropinocytosis or an endocytosis-independent mechanism, including the carpet, 
inverted micelle, barrel stave pore and toroidal models (Figure 5).2,15 CPPs can be 
organized into cationic, hydrophobic and amphipathic groups.15 
 
Figure 5: Different mechanisms used by CCPs to cellular internalization. Adapted.
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1.3.1. Peptides in Tumor Targeting Therapy 
 Since their discovery about 30 years ago, TTPs, also known as tumor homing 
peptides, have become an useful tool for tumor therapy and diagnosis, due to their 
ability to mimic targeting properties of antibodies without macromolecular 
disadvantages.14 Thus, TTPs bind to specific addresses of tumor tissues with low to no 
affinity to normal cells. In comparison to antibodies, TTPs have a much smaller size 
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(less than 30 amino acids on average), which improves tissue penetration, low 
immunogenicity and a production process more simple and at a much lower cost.2,14 
Relating to SMIs, peptides are more biocompatible and amenable to introduce 
structural modifications.15,30,31  
Today, there are more than 740 TTPs identified, being RGD and NGR, 
discovered in 1980, the most studied.2,11,13–15 Besides TTPs with targeting tumor cells 
ability, TTPs able to target vascular and lymphatic tumor systems and tumor 
microenvironment cells were found.2,15 In the last 5 years, this vascular homing 
peptides were intensively investigated since they can destroy tumor microvasculature, 
promoting tumor cell death by direct accessibility from healthy vasculature system, not 
needing extravasation to reach the target that may be compromised by poor blood 
perfusion and high interstitial pressure.2,12,15,17 Furthermore, vasculature systems are 
more genetically stable, unlikely to acquire drug resistance.13 More recently, cancer 
therapy research integrated tumor microenvironment homing peptides, due to their 
important role in metastasis formation.2,14,15 
Although “targeting” is a recent concept, there are already classic peptides with 
tumor targeting ability utilized in clinical practice. For example, goserelin, a 
gonadotropin releasing hormone (GnRH) receptor agonist, is utilized for breast and 
prostate cancer therapy, due to its capacity to suppress the expression of testosterone 
and estrogen. Another example is octreotide, a somatostatin receptors (SSTR) agonist, 
utilized for treatment of growth hormone producing tumors (Figure 6).32 
 
Figure 6: Chemical structures of classic peptides with targeting ability. Adapted.
33,34
 
1.4. TTPs Discovery Techniques 
TTPs can be developed by molecular modeling when the X-ray structure of the 
receptor is available or by screening combinatorial peptide libraries with known 
molecular targets. These libraries can be divided into three main types: focused Abs 
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libraries (natural peptides or antibodies), one-bead one-compound (OBOC) libraries 
and phage display peptide libraries.14 In focused Abs libraries, peptides displaying 
specific antigen affinity are identified by amino acid sequences of complementarity 
determining regions (CDRs) of Abs, variable domains of Abs responsible for antigen 
recognition. However, recent findings show that not all CDRs regions are important for 
antigen binding and CDRs outside regions can contribute to its coupling.  
OBOC library screen methods are based on a chemical technique composed of 
90 μm-sized beads, each containing a different peptide ligand.14 In this technique, 
peptides are subject to a split mix strategy and screened against cell surface targets 
previously labeled. The advantage of this method is the possibility of incorporating non-
natural components in peptides ligands, like D-amino acids, cyclization and 
branches.14,35 
Phage display peptide libraries, mostly utilize to identify TTPs, are focused in a 
biological approach that creates a random combinatorial library, through genetic 
modifications of the DNA of phages, allowing the expression of surface ligands.14,36 
These type of libraries are exposed to protein targets (for instance, through whole cells, 
tissue samples and live animals) and then phages with binding capacity are analyzed 
by DNA sequencing, immunohistochemistry, in vivo imaging and mass spectrometry to 
identify target-binding peptides.13,14,37 In this method, there are multiple repetitions of 
selection and amplification steps (panning) to enrich the number of surface targets with 
the highest binding affinity, allowing the screening of a large number of peptide 
sequences without the need to have previous knowledge of the molecular composition 
of the binding site (Figure 7).14,35  
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1.5. Targeted Drug Delivery Systems 
Nowadays, both in academia and industry, the development of site-specific drug 
delivery systems (DDS) and efficient drug targeting approaches are being investigated 
to surpass the systemic “off-target” effects shown by antitumor therapies and to 
maximize their therapeutic efficacy.11,13,17,38  
Generally, the starting point of a drug targeting approach is a prodrug 
construction by a covalent modification of the drug with a carrier unit, a small moiety 
that inactivates the pharmacological effect of the drug during delivery and provides 
adequate pharmacokinetic properties.38 The carrier unit and the drug are attached by a 
chemical linker that controls the intracellular release of the drug (for example, acid-
cleavable and reduction-sensitivity spacers, where environment changes trigger their 
intracellular cleavage).11 
Alternatively, delivery vehicles (also known as particulate drug carriers) may be 
used to encapsulate the drug and control its biodistribution (Figure 8).38 Delivery 
vehicles are molecular assemblies with high loading capacity that confine the drug in a 
loading space (commonly the core of the particulate), providing protection against 
enzymatic inactivation. Due to the absence of covalent conjugation to entrap the drug 
molecule, delivery vehicles allow the use of a single carrier unit to formulate several 
drugs. Furthermore, the composition and size of vehicles can be adjusted to determine 
particulates with ideals physicochemical properties, which diversifies their stability and, 
per consequence, the rate of drug release. In the field of cancer therapy, the ideal size 
is in the 50-150 nm range (nanocarriers) to avoid extravasation into normal tissues 
and, at the same time, enabling the extravasation from most tumor blood vessels into 
tumor interstitium.11  




Figure 8: Delivery vehicles used in targeted DDS to cancer therapy application. Adapted.
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The most common nanocarriers are liposomes, polymeric nanoparticles and 
block copolymer micelles. Whereas liposomes are lipid molecules orderly in a lamellar 
disposition, generally used as unilamellar vesicles, polymeric nanoparticles are 
biocompatible polymers where the drug is entrapped to a vesicle surrounded by a 
polymer membrane or dispersed in a matrix, named nanocapsules or nanospheres, 
respectively. Moreover, block copolymer micelles are characteristically spherical 
amphiphilic copolymers, whose loading space accomodates hydrophobic drugs, and 
the hydrophilic outer layer promotes dispersal of the micelles in water.17 As drug 
delivery nanocarriers or imaging probes, nanoparticles have been shown more 
advantages in comparison with others nanocarriers, including the better tumor 
penetrating ability, higher ability to carry cargos and quality of imagine information.12 
However, the prodrug approach tends to prevent premature drug liberation and 
decreases inert materials quantity.38 
It is common to conjugate hydrophilic polymers, like poly(ethylene glycol) 
(PEG), onto carrier units’ surface to inhibit their uptake by the reticuloendothelial 
system, therefore prolonging the in vivo half-life and, consequently, the targeting 
potential. PEG forms a hydrophilic barrier around the particulate that blocks proteins 
and other macromolecules to reach the particulate surface, including antibodies raised 
against the particulate. In this case, the ligand must be conjugated to the terminal of 
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the stabilizing component to prevent the shielding effect that leads to a severe 
reduction of ligand-receptor interaction.17 
For the majority of targeted DDS, the cargo needs to be internalized into cells to 
exercise its pharmacological activity. After the peptide-receptor interaction, conjugates 
can be internalized through receptor-mediated endocytosis, where they may move 
through the early and late endosomes and finally, into lysosomes. Furthermore, to 
exert pharmacological activity, the cargo has to exit these organelles to reach the 
cytosol or the nucleus (the two sites of action of intracellularly active drugs). In 
lysosomes, due to enzymes and/ or pH dropping, the linker between the cargo and the 
carrier is broken, enabling the cargo escape to cytosol while, in the meantime, 
receptors are recycled (Figure 9).17,39 If the microenvironmental conditions do not allow 
the rapid disintegration of the particle, the diffusion of the drug out of the endosomes is 
necessary, through lytic peptides, pH-sensitive polymers and swellable dendritic 
polymers.17,32 In the case of nanocarriers, internalization of the drug can occur without 
concomitant internalization of the particulate, due to atypical conditions of the tumor 
microenvironment (like acidic pH, presence of lipases, enzymes and oxidizing agents), 
which results in the accelerated release of the drug and its diffusion into tumor cell, 
through passive diffusion or active transport.17 
 
Figure 9: Schematic cell internalization process for targeted DDS. Adapted.
39
 
1.5.1. TTPs as Carrier Units in DDS 
During the past two decades, more efficient functional peptides were 
developed.15 In particular, TTPs have been studied as carrier units of peptide-based 
drug conjugates (PDCs), an emerging class of prodrugs, formed through the covalent 
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attachment of a specific peptide sequence to a drug via a cleavable linker (Figure 
10).11,38 
 
Figure 10: Schematic representation of PDCs. A) Schematic representation of tumor targeting approaches 
using PDCs; B) Necessary key-properties of PDCs components. Adapted.
11
 
To ensure drug delivery to tumor cells, is necessary to improve stability in vivo 
and evaluate pharmacokinetic properties of PDCs, that will improve selectivity for 
cancer cells.2 Generally, peptides have relatively large size, hydrophilicity and 
hydrogen-binding potential, which makes them unsuitable to be orally administered, 
due to the difficult passage by intestinal mucosal barriers. Thus, the parenteral route is 
the most chosen to delivery TTPs conjugates.39 Moreover, it is possible to conjugate 
multiple TTPs to a single delivery vehicle to increase cargo delivery and prevent 
peptides degradation by proteolysis, by blocking N- and C-terminally, through 
incorporation of D-amino acids (unnatural amino acids), cyclization and insertion of 
reduced peptide bonds.14,31  The most commonly utilized cyclization method is disulfide 
bridge formation from two Cys residues.40 Other important property of PDCs that 
promotes efficient delivery of drugs is the internalizing ability of some TTPs into cell 
membranes.17 Since some TTPs cannot internalize their cargos, CPPs-TPPs 
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conjugates have been developed, which contribute for a better intracellular drug 
delivery mechanism (Figure 11).11  
 
Figure 11: Principal of cell-selective peptide targeting and delivery. A) TTPs without internalization ability; 




TTPs conjugates with cytotoxic drugs, in addition to being exhaustively studied 
in several preclinical and clinical studies, were also investigated as carriers of 
radioisotopes.12,30 In this case, there is an attachment of a radio-ligand to the peptide 
carrier through the aid of a chelator, such as diethylenetriaminepentaacetic acid 
(DTPA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), but 
there is no release of the cargo, since it is an unnecessary process. Radionuclides like 










Nowadays, cytotoxic drugs used in antitumor therapies are not very effective 
and cause serious adverse effects due to their poor ability to distinguish tumor cells 
from the normal cells. To solve this problem, molecular systems based on conjugation 
of a cytotoxic drug and an antibody responsible for the tumor targeting ability are 
available on the market. However, these therapeutic conjugates have a high economic 
cost and structural disadvantages. On the other hand, since their discovery about 30 
years ago, tumor targeting peptides (TTPs) are able to recognize specifically tumor 
targets, such as Abs but without their structural disadvantages. Thus, the use of these 
peptides in targeted therapeutic delivery systems to cure cancer patients is very 
promising. However, many of the features of these peptides are not yet fully 
understood. 
The aim of this work is to review the literature regarding tumor targeting 
approaches and to organize and summarize the TTPs that contributed in a significant 
way to the advances of this field, including the development of therapeutic conjugates. 
This way, it is intended to focus their structural and functional characteristics, 
addresses, structure-activity relationship (SAR) studies, internalizing capacity and 
application in the development of drug conjugates. 
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3. Materials and Methods 
3.1. Materials 
In this work journal articles were used, mainly review articles published in 
several international scientific journals, as sources of information. These articles were 
collected and selected from the National Library of Medicine’s search service (PubMed 
database), that provides access to millions of references in United States National 
Library of Medicine and other related databases. 
3.2. Methods 
Firstly, the literature review started with the collection and reading of articles 
(especially review articles) regarding tumor targeting-based approaches and peptides 
with tumor targeting abilities. Then, the most representative peptides of the scientific 
advances made in this field were selected based on these articles. The selection 
criteria were based on the number of articles that referred the respective peptides, the 
quantity of information available, the actuality of the articles and the tumor addresses. 
Finally, others articles of each selected peptide were collected to summarize 
information of each, in order to highlight structural and functional features, addresses, 
structure-activity relationship (SAR) studies, internalization capacity and applications in 
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Table 2: Key-words and expressions utilized to obtain the selected articles. 
Key words and expressions References 
Tumor targeting internalizing peptides review 
17
 
Tumor targeting peptides review 
7,11,12,14–16,30–32,37,41
 
Tumor homing peptides review 
2,13,18,19,42
 
Peptides targeting cancer review 
5,35
 
Peptide drug conjugates review 
38,39
 
Tumor therapy review 
1,8,10,26
 
Cancer therapies review 
3,25
 
Novel cancer treatment review 
4,43
 









NGR structure activity relationship 
67
 















Bombesin receptor cancer review 
74
 




























Following the literature review, nine peptides were selected: RGD, NGR, F3, 
Octreotide, LyP-1, Bombesin, Angiopep 2, CREKA and M2pep. These peptides were 
organized according to the targeting localization type: tumor vasculature, tumor 
lymphatic vessels, tumor cells and tumor microenvironment. Relevant and recent 
information concerning others TTPs was collected and organized (Annexes 1 and 2). 
4.1. Peptides Targeting Tumor Vasculature 
4.1.1. RGD 
The RGD tripeptide (Arg-Gly-Asp) is the most widely investigated among all 
TTPs (Figure 12A).14 This tumor targeting peptide was discovered by phage display 
techniques, as an essential cell recognition site of several blood, extracellular matrix 
(ECM) and cell surface proteins like fibronectin, vitronectin and fibrinogen.2,7,15,35,42,48,49 
The RGD peptide can selectively target endothelial cells of tumor blood vessels 
expressing αvβ3 and αvβ5 integrins receptors.
13,14 
Integrins are cell adhesion receptors for ECM proteins, immunoglobulins, 
growth factors, cytokines and matrix-degrading proteases. These divalent 
heterodimeric membrane glycoproteins, composed by non-covalently associated α- 
and β-subunits are expressed at the surface of normal tissue and blood vessels.7,14,42,55 
Despite 24 integrins subtypes being known, endothelial cells of angiogenic vessels 
express a different set of integrins, being αvβ3 and αvβ5 integrins specifically 
upregulated in tumor vasculature.5,14,35  Furthermore, αvβ3, αvβ5, α5β1, α6β4, α4β1 and 
αvβ6 integrins are also overexpressed in tumor cells, being the most studied integrins in 
cancer.51 However, RGD can be recognize by 8-12 of the 24 known integrins.35 The 
activation of this receptors triggers cellular pathways involved in tumor angiogenesis 
and metastasis promotion.11,37 In particular, αvβ3 integrin regulates intracellular 
signaling that protects tumor cells from the anti-proliferative action of anti-tumor 
drugs.37  
There are several RGD recognition sites in α and β subunits of integrins. In all 
cases, these binding sites are localized at or near a binding site for divalent cations, 
being the β3 subunit of αvβ3 integrins the primary site for RGD binding.
48,57,58 Adjacent 
binding sites of divalent cations helps to keep a favorable binding conformation. By 
itself, a simple linear RGD ligand presents low affinity for integrins receptors. This is 
Developments in Tumor Targeting and Internalizing Peptides 
32 
 
related to the conformation freedom of the RGD peptide that determines its 
selectivity.5,60 For example, the RGD-TNFα conjugate is promising, although the 
presence of four Cys residues in the peptide structure makes it difficult to fold in a 
homogeneous manner, compromising its effectiveness.14,42 This way, to obtain a 
biologically active conformation, several cyclic RGD analogues (cRGD) were 
developed via “head-to-tail” modification, to create a more rigid structure, more stable 
at neutral pH and better at resisting proteolysis.5,52,54,60,62  
In cyclic peptides, the RGD motif is flanked by other amino acids to build a ring 
system, which may induce receptor affinity or selectivity and other biological 
properties.55 cRGD peptides include RGD-4C (ACDCRGDCFCG) and Cilengitide 
(Figure 12).5,54 Cilengitide, the salt of the cyclic pentapeptide with the sequence Arg-
Gly-Asp-DPhe-(NMeVal) - c(RGDf[NMe]V) - demonstrated encouraging results in 
patients with glioblastoma, which implies penetration of the blood brain barrier (BBB), 
although clinical trials have not fully proved its effectiveness.2,7,11,19,35,37,59 Cilengitide 
can act as a specific antagonist of αvβ3 and αvβ5 integrins.
9,35 Others structural 
modifications in Cilengitide, including the introduction of the unnatural D-conformation 
of Phe amino acid and N-methylation, improve its receptor affinity and pharmacokinetic 
properties.60 More recently, three PDCs were developed based on this pentapeptide, in 
which the mutilated Val was mutated to Lys or Ser amino acids for the creation of a 
primary amine or hidroxyl group, potential sites for drug conjugation.35 
 
Figure 12: Chemical structure of RGD peptides. Adapted.
55
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On the other hand, others RGD peptides were designed to improve tumor 
penetration.2 Internalizing RGD (iRGD) is a 9-amino acid, disulfide-bridged cyclic 
peptide with the ability to facilitate the internalization into endothelial cells, in addition to 
target αvβ3 integrins.
2,13,14,97 This extra capacity allows the intracellular uptake of the 
conjugated cargos, contributing to the internalizing process of antitumor drugs. The 
penetration capacity is due to a specific sequence contained in the peptide, the 
sequence R/KXXR/K (X: any amino acid) at C-terminal, named C-end Rule (CendR), 
that binds to neuropilin-1 (NRP-1), a transmembrane protein expressed on membranes 
of endothelial cells that, when activated, triggers downstream signal pathways to 
increase cell permeability.2,13,14,63 After iRGD connection to an integrin, a protease 
cleaves the peptide to produce CRGDK/R and exposes the CendR motif that can 
interact with NRP-1 receptors (Figure 13).55,61 The CendR penetration is receptor-
mediated, energy-dependent, effective with small molecules and causes extravasation 
of the peptide (or their cargos) within minutes.61  
 
Figure 13: Penetration mechanism of iRGD. Taken from 
55
 
The current clinical trials involving RGD motif (Table 7, Annex 3) are testing its 
application not only in tumor therapy, but also in diagnostic imaging, through 
conjugation with cytotoxic drugs, peptides or proteins, nucleic acids, radionuclides and 
contrast agents.  For instance, the first RGD-modified positron emission tomography 
(PET) tracer in clinical trials was Galacto-RGD, an RGD analog obtain by cyclization of 
a RGD pentapeptide and modification of Phe to the unnatural configuration – 
c(RGDfV).5,52 
More specifically, in clinical trials, the improvement of the delivery and therapy 
efficacy of tumor therapy agents when conjugated with RGD peptide or analogues, 
Developments in Tumor Targeting and Internalizing Peptides 
34 
 
namely cytotoxic drugs like paclitaxel (PTX) and doxorubicin (DOX), therapeutic 
peptides such as KLAKLAKKLAKLAK (KLA), cytokines like tumor necrosis factor α 
(TNFα), interferon-γ (IFN-γ) and interleukin-12 (IL-12), Abs and their fragments such as 
the Fc fragment of immunoglobulin G (Ig G) was proven. 12,13 Furthermore, RGD-
targeted nanocarriers benefit of the possibility to enhance the internalization process 
via integrin-mediated endocytosis, instead of standard uptake mechanisms after drug 
release, such as the RGD-modified PEGylated liposome-encapsulates DOX.5,55 
4.1.2. NGR 
The NGR tripeptide (Asn-Gly-Arg), discovered by the in vivo phage display 
method, specifically binds to tumor endothelial cells expressing the aminopeptidade N 
(APN) receptor, also called CD13.13,37,64 Like RGD, this sequence are encountered in 
natural proteins, such as fibronectine.36 
CD13 is a membrane-bound and highly glycosylated metalloproteinase, with a 
significantly role in protein degradation and regulation of cytokines, antigen 
presentation, cell proliferation and migration and angiogenesis.13,42,66 Although it is 
overexpressed in tumor blood vessels, CD13 can be find in tumor cells, fibroblasts and 
pericytes, and in normal tissue like mast cells, keratinocytes, proximal renal tubules, 
myeloid cells and epithelial cells.13,36,42 There are several CD13 isoforms, which could 
explain the binding of NGR peptides to tumor vasculature but not to other CD13-rich 
tissues.14,42,68 Furthermore, in endothelial cells, CD13 interacts with galectin-3 (a 
proangiogenic protein) in a carbohydrate recognition-dependent manner, forming a 
complex that, together with the abnormal architecture of tumor blood vessels, may be 
related to differential glycosylation or conformational changes and, therefore, with the 
selectivity of NGR motif to endothelial CD13.36 
Recent studies suggest that NGR can interact with integrins by a spontaneous 
and unusual mechanism that consists in the rapid deamidation of the Asn residue, 
through the formation of a succinimide ring, followed by hydrolysis, forming 
isoaspartate and transforming NGR into the isoaspartate-glycine-arginine (isoDGR) 
derivate, a cell adhesion motif with high affinity for αvβ3 and αvβ5 integrins (Figure 
14A).36,65,68,69,98 Thus, isoDGR can promote endothelial cell adhesion, having a binding 
site located within the RGD binding pocket, being as well an antagonist of ανβ3 
integrin.36,65 However, mostly in injured tissues and wound healing, cells produce 
protein-L-isoAsp-O-methyltransferase (PIMT), an enzyme that converts isoaspartate to 
aspartate, causing the deactivation of isoDGR function (Figure 14B).36 








Several therapeutic molecules have been conjugated to NGR peptides, namely 
cytotoxic drugs, therapeutic proteins, proapoptotic peptides, viral particles, imaging 
agents and DNA complexes. Specific examples include conjugation of NGR with DOX, 
the proapoptotic peptide D and TNFα.13,64 This conjugates may penetrate cell 
membrane via receptor mediated endocytosis.68 
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Generaly, small cyclic NGR peptides are more selective than linear forms, due 
to conformational constraining that improves binding affinity. The most effective cyclic 
NGR peptides developed are c(CNGRC) and (KNGRE)-NH2 (Figure 15A and B). The 
c(CNGRC) was designed with the disulfide bonding of the two Cys residues, increasing 
the targeting efficiency due to stabilization of the bent conformation.14,64,65,68 
Particularly, cCNGRC-TNFα (currently tested in Phase III clinical trials) (Table 8, Annex 
3) have shown a promising potent anticancer activity due to its capacity to facilitate 
drug penetration and infiltration of immune cells, since TNFα increases intracellular 
adhesion molecules on endothelial cells, expression of pro-inflammatory cytokines and 
recruitment of tumor-specific cytotoxic T cells.13,64 Moreover, to surpasses the disulfide 
bond disadvantages (susceptibility to biodegradation and chemical modification), the 
“head-to-side-chain” amide bond cyclized peptide - c(KNGRE)-NH2 - was 
developed.65,68 Other examples of NGR peptides are GNGRG, NGRAHA and 
CVLNGRMEC.64 SAR studies of GNGRG (Figure 15C) suggest that the linear NGR 
peptide without disulfide constraints is more thermodynamically favorable when its 
configuration is based in a β-turn in Gly3 and Arg4 and hydrogen bonding interactions 
between Asn2 and Cys5. Thus, like the RGD receptor binding, there is necessary a 
folded structure for receptor binding, with intramolecular stabilizing interactions (like 
hydrogen bonds) that stabilize the folded state.67 




Figure 15: Structure of common NGR peptides. Adapted.
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Similar to the iRGD, internalizing NGR (iNGR) possesses the CendR motif and, 
therefore, the ability to bind to NRP-1 and penetrate tumor endothelial cells.13 
4.1.3. F3 
F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) is a 34–amino acid 
fragment of the human high mobility group protein 2 (HMG2N), a nucleosomal protein 
that participates in unfolding of chromatin structure, facilitating the transcriptional 
activation of genes.44,46,47,99 This tumor targeting peptide, discovered by the phage 
display libraries technique, binds to the nucleolin (NCL) receptor overexpressed in 
tumor cells, tumor endothelial cells and in a bone marrow subpopulation, precursor of 
endothelial cells.44,46,99 
NCL is a non-ribosomal protein important to polymerase I transcription, being 
found in high quantity in the cell nucleolus, where ribosome assembly and ribosomal 
ribonucleic acid (rRNA) transcription occurs. Other nucleoplasmic NCL receptors are 
responsible for the regulation of gene expression, mostly of oncogenes, and genome 
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stability, due to its interaction with RNA polymerase II. Moreover, in cytoplasm, 
nucleolin interacts with messenger ribonucleic acid (mRNAs) coding proteins related 
with cell proliferation and apoptosis. NCL structure can be divided in three domains: the 
negatively charged N-terminal domain (with acidic regions due to the abundance in 
aspartic acid and glutamic acid) disunited by basic stretches, the central domain 
containing fours RNA binding domains and the C-terminal domain, predominantly with 
Gly, Arg and Phe residues.45,99 
In tumor cells and tumor endothelial cells, overexpressed NCL promotes the cell 
internalization of several ligands related with angiogenesis, proliferation and 
apoptosis.45 F3 peptide can be internalized by NCL due to its NH2-terminal domain (via 
receptor-mediated endocytosis) and carried into the nucleus after cell penetration.14,99 
SAR studies show that the D-amino acid form of F3 has equal internalization ability, 
although it is not efficiently transported into the nucleus. This internalizing mechanism 
is not defined, but studies have shown energy dependence for the mechanism 
occurrence and the possibility of F3 interaction with NRP-1.14,46  
F3 peptide was conjugated with radiotherapeutic agents for tumor therapy, such 
as 225Ac, 213Bi and 111In.13 Nonetheless, there are no studies about the conjugation 
between this tumor targeting peptide and cancer drugs.19 
4.1.4. Octreotide 
SST is an endogenous acid popypetide with the sequence Ala-Gly-c(Cys-Lys-
Asn-Phe-Phe-Trp-LysThr-Phe-Thr-Ser-Cys), with high-affinity for SSTRs. This peptide 
acts as an endogenous inhibitory regulator and has various biological functions, 
including inhibition of many hormone secretions, cell survival and cell proliferation.41,83 
However, SST possesses an extremely short half-life (about 2-3 minute), due to its 
rapid inactivation by peptidases, being limited its clinical utility.41,86 Thus, several 
synthetic SST analogues were developed to treat endocrine tumors, through 
shortening of its sequence and introducing D-amino acids to increase the half-life time. 
SAR studies demonstrate that the key sequence for binding and biological activity was 
the β-turn fragment Phe-Trp-Lys-Thr sequence, the residues 7-10 of the SST, in 
addition to the existing disulfide bridge.83,86  After interacting with the receptor, SST 
analogues are rapidly internalized into tumor cells (via SSTR-mediated endocytosis), 
being able to translocate to the nucleus.83,84 Furthermore, these analogues have been 
used to developed conjugates with application in targeting therapy, radiotherapy and 
tumor imaging (Figure 16).83  




Figure 16: Schematic chemical structures of SSTs and analogues. Taken from 
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SSTRs are transmembrane G-protein coupled receptors expressed in the 
central nervous and immune systems, endocrine tissue, gastrointestinal tract and skin, 
playing different physiological roles.35,41,85 There are five distinct SSTR subtypes, being 
the SST2R and SST5R receptors overexpressed in various types of tumors, not only in 
tumor cells, but also in tumor endothelial cells.32,83 
Octreotide, a cyclic octapeptide with the sequence D-Phe1-c(Cys2-Phe3-D-
Trp4-Lys5-Thr6-Cys7)-Thr8-ol), is an agonist of SSTRs, namely SST2R subtype, that 
mimics the natural SST hormone, although it is a more potent inhibitor of growth 
hormone, insulin and glucagon.32,41,86 Nowadays, octreotide is utilized successfully 
against growth hormone-producing tumors in many countries.32,41 The remarkable 
feature of octreotide is its stability towards degradative enzymes.84 The β-turn is a 
stable conformation due to the N- and C-terminal of the D-Phe1 and Thr(ol)8 or Trp8-
NH2 amino acids by intramolecular hydrogen bonds that stabilize the conformation of 
the peptide.86 Besides, SAR studies also showed that both C- and N-terminal residues 
of octreotide are important for binding affinity.39 
Potent chemotherapeutics agents including PTX, camptothecin (CPT), DOX 
and methotrexate (MTX) have been used for the development of octreotide 
conjugates.32,83 For example, two molecules of PTX were coupled to the N-terminal of 
octreotide by an ester bond and utilizing a succinic acid spacer (Figure 17).32 More 
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recently, the redox-sensitive prodrug octreotide(Phe)-polyethylene glycol-disulfide 
bond-paclitaxel - OCT(Phe)-PEG-ss-PTX - was design.41 On the other hand, the first 
radiolabeled SST analog clinically applied was the (111In-DTPA0)-octreotide.5,84  
 
Figure 17: Chemical structure of ester bond-linked PTX-octreotide. Adapted.
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4.2. Peptides Targeting Tumor Lymphatic Vessels 
4.2.1. LyP-1 
LyP-1 is a cyclic nonapeptide (CGNKRTRGC) with the capability to target tumor 
lymphatic vessels and tumor cells in hypoxic areas, by interaction with p32, a 
mitochondrial/ cell surface protein receptor (Figure 18).14,16 LyP-1 can penetrate the 
plasma membrane into the cytoplasm and nucleus.72 By itself, the linear form of LyP-1  
peptide has cytotoxic activity, since it accumulates in tumor hypoxia areas, decreasing 
the number of lymphatic vessels and promoting apoptosis of tumor cells undergoing 
stress.14,70,72 For instance, LyP-1 was used to improve the delivery of DOX-loaded 
PEGylated liposomes.15 
 




Figure 18: Cyclic structure of LyP-1. Adapted.
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The p32 receptor, also called as hyaluronic acid binding protein 1, is 
overexpressed on tumor lymphatics, tumor cells and TAMs.15,16 However, the 
molecular mechanism of LyP-1 recognition by the receptor is poorly understood.72 On 
the other hand, LyP-1 internalization is similar to iRGD penetrating mechanism. The 
binding of LyP-1 to the p32 receptor triggers its proteolytic cleavage into tLyP-1 
(CGNKRTR), allowing the exposure of CendR motif and the binding to NRP receptor.71  
4.3. Peptides Targeting Tumor Cells 
4.3.1. Bombesin 
Bombesin is a 14-amino acid neuropeptide (QQRLGNQWAVGHLM), containing 
high affinity to the gastrin realizing peptide receptor (GRPR), a G protein-coupled 
receptor overexpressed in tumor cells, also named as bombesin receptor type 2 
(BB2).11,39,41,73,75 
Mammalian bombesin receptors (BBRs) can be divided into four receptor 
subtypes: neuromedin B receptor (NMBR or BB1), GRPR and bombesin receptor 
subtypes 3 and 4 (BB3 or BRS-3 and BB4, respectively).35,73 These receptors can 
naturally occur in central nervous system (CNS) and in peripheral tissues, having a 
wide spectrum of actions in physiological processes.74 The activation of BBRs 
promotes the release of others peptide hormones like insulin, glucagon, prolactin and 
gastrin and cytokine activity, being able to act as a growth factor.75 Although there are 
four subtypes of BBRs, the natural ligand of BB3 is unknown and it has low affinity for 
bombesin peptides.74 As tumors can secrete bombesin to stimulate tumor growth, 
tumor targeting approaches based on this peptide may interrupt tumor autocrine-
growth.35,74   
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BBRs antagonists can block the tumor growth stimulated by bombesin peptides. 
While BBRs agonists are internalized via receptor-mediated endocytosis, their 
antagonists have low to no internalization ability.74 To enhance bombesin antagonist 
activity, it is possible to cleave the peptide bond in its active site (positions one to five 
or Tyr4-Lys3, and Tyr4-D-Phe12), introduce a nonpeptide between C-terminal and 
adjacent amino acid residues or replace them, incorporate D-amino acids, ester 
modifications, disulfide bridges and non-peptide bonds.75 The selectivity of GRPR 
antagonists depends mostly on interactions with amino acids Thr297, Phe302, and 
Ser305 in the fourth extracellular domain of the receptor. All of these amino acid faces 
forward in the binding pocket, demonstrating that cation and hydrogen bonding 
interactions are essential to occur between antagonists and the three respective amino 
acids.76,77 Examples of GRPR antagonist are JMV594 [(D-Phe6, Stat13)Bn(6–14)], and 
JMV641 [D-Phe-Gln-Trp-Ala-Val-GlyHis-Leu(CHOH-CH2)-(CH2)2-CH3].
76 
The bombesin sequence D-Tyr6-β-Ala11-Phe13-Nle14 is responsible for the 
rapid cell internalization in all three types of BBRs, being able to be used to develop 
targeting conjugates based in bombesin.32,41 For instance, bombesin conjugates 
through the coupling with MTX via a Lys spacer were developed, as well as DOX via a 
glutaric acid spacer and taxol using a PEG linker.11,39 Others conjugates of bombesin 
were prepared by loading them with CPT, PTX, mitochondria-disruptive peptides, 
marine toxins and siRNA.35 Moreover, a large number of bombesin analogues were 
conjugated with radioisotopes like 99mTc, 111In and 125I and other contrast agents, and 
bivalent probes  with 64Cu as the cargo of the conjugate were prepared.74 
4.3.2. Angiopep 2 
Angiopep 2 is a 19-amino acid peptide with the ability to cross the BBB, 
targeting specifically the low-density lipoprotein receptor-related protein 1 (LRP-1).14  
The BBB is responsible for brain protection from potentially harmful substances 
circulating in the bloodstream and for maintaining the homeostatic environment of the 
central nervous system. This neurovascular unit is constituted by endothelial cells with 
extensive tight junctions, neurons, astrocytes and a contractile apparatus of smooth 
muscle cells and pericytes.89,91  
LRP-1 is a member of the large receptor family of low density lipoprotein (LDL). 
Like other receptors of this family, the modular structure of LRP-1 includes Cys-rich 
complement-type repeats, a cytoplasmic domain and a transmembrane domain. This 
receptor is highly expressed in astrocytes, smooth muscle cells, neurons and perycites, 
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but is not as expressed in the endothelium.89,91 LRP-1 mediates the BBB transcytosis 
process for several ligands such as lactoferrin, thyroglobulin, α2 macroglobulin and 
tissue-type plasminogen activator. In addition to being expressed on the surface of the 
BBB and controlling its permeability, LRP-1 is also present on a variety of tumors, 
mainly in high malignant glioma cells, participating in the cytoskeleton organization and 
in the adhesive complex turnover by modulating integrins functions in malignant 
cells.88,89,91 Thus, although BBB has low permeability for small-molecule drugs, 
angiopep 2 is capable to penetrate the BBB and target brain tumor cells, using the 
same receptor-mediated transporter.14,32,87,90 
The most promising drug conjugate based on angiopep 2 consists in a 19-
amino-acid linear angiopeptin-2-PTX conjugate (GRN1005). This peptide drug 
conjugate is composed by three PTX molecules linked to the two Lys residues 
(positions 5 and 9) of angiopep 2 and to the N-terminal Thr, by cleavable ester 
linkers.32,35 GRN1005 crosses the BBB by LRP-1 receptor-mediated transcytosis and is 
distributed broadly throughout brain parenchyma (Figure 19).32,88 Howerver, the exact 
molecular mechanism of angiopep transcytosis remains unknown.90 Further studies 
showed that GRN1005 is not a substrate for P-glycoprotein-mediated drug efflux, 
improving anti-tumor efficacy.88  
Other angiopep 2 drug conjugates were created, including angiopep-2–
doxorubicin, angiopep-2–dimethylglycine etoposide and angipep 2–trastuzumab 
(efficient against HER2-positive intracranial tumors).35 




Figure 19: Internalization of GNR1005 through BBB (A) and tumor cell surface (B). Taken from 
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4.4. Peptides Targeting the Tumor Microenvironment 
4.4.1. CREKA 
CREKA is a linear pentapeptide (Cys-Arg-Glu-Lys-Ala) identified by phage 
display libraries that targets fibrin-fibronectin complexes deposited in tumor vessels 
walls and tumor interstitial spaces, forming a meshwork of clotted plasma proteins 
detectable only in tumor tissues.14,15,78,81 Moreover, CREKA can induce tumor clotting, 
creating new binding sites in a self-amplifying effect. The exact binding site of the 
CREKA peptide is still unknown.  
The bioactive conformation of CREKA is based on a turn-like structure where 
the charged groups of Glu, Lys and Arg form stable intermolecular interactions.82 
Moreover, the sulfhydryl group of the Cys residue of CREKA is not required for binding 
interactions with its receptor, being the preferred site to conjugate the peptide with 
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other moieties.11,78 This knowledge promoted the design of CREKA-based peptides 
with enhanced features. For example, the CR(NMe)EKA has a N-metil derivate that 
increase tumor-homing response by protecting the peptide against proteolytic 
degradation (Figure 20).82 Moreover, in order to block the action of tumor-associated 
platelets on tumor metastatic progression, created liposomal nanoparticles bearing 
CREKA and ticagrelor (a platelet inhibitor) were created.80 
 




The sequence YEQDPWGVKWWY, termed M2pep, identified using a phage 
display strategy, is a unique M2-selective peptide that specifically recognizes and 
internalizes M2 cells, including TAMs, having low affinity to others leukocytes.14,15,94  
Macrophages are phagocytic cells originated from circulating blood monocytes 
that extravasate into tissues and differentiate into macrophages with several functional 
phenotypes. Whereas M1 macrophages phenotype is stimulated by mediators, like 
interferon γ or lipopolysaccharide, resulting in a pro-inflammatory and microbial 
functional phenotype, M2 macrophages are stimulated by IL-4 and IL-13 in tissue 
remodeling and inflammation resolution cases.94  TAMs are originated from circulating 
monocytes, differentiating within the tumor microenvironment, in M1 or M2 activated 
macrophages.93,95 Most of TAMs are M2-like macrophages and have the ability to 
produce immunosuppressive cytokines and have low antigen-presenting and co-
stimulating capacity, facilitating tumor progression by suppressing the adaptive immune 
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response.93,94 Moreover, TAMs are responsible for immune evasion, metastasis, 
angiogenesis and matrix remodeling.14,92,93 While the increased density of TAMs is 
related with drug resistance, radiotherapy induces macrophage aggregation, creating 
radio-protective effects.93 
To enhance M2 macrophage-binding affinity of M2pep, a cyclic analog was 
build, the Cys-decafluorobiphenyl-Cys disulfide-cyclized M2pep c[DFBP-M2pep(RY)].40 
More recently, studies have shown that the divalent display of M2pep improves M2 
macrophage-binding activity, while tetravalent display leads to the loss of selectivity of 
macrophages phenotype. Moreover, divalent and tetravalent displays of M2pep 
([M2pep]2-Biotin and [M2pep]4-Biotin) exhibit M2 macrophage cytotoxicity. Further 
studies with M2pepKLA analogues ([M2pep]2-[KLA] and [M2pep]2-[KLA]2) showed 
improvement of the cytotoxic activity (Figure 21).14,94,95 On the other hand, the 
optimization of the serum stability was achieved through “head-to-tail” cyclization, 
modifying linear M2pep(RY)Biotin with two flanking Cys, enabling disulfide cyclization, 
and by the replacement of the triLys spacer to D-Lys. Furthermore, N-terminal 
acetylation of M2pepBiotin gives protection from exolytic degradation.96 
 










Through the analysis of the nine selected peptides, they can be divided in 
peptides that directly target tumor cells and peptides that target adjacent cells localized 
in their surrounding environment, including blood and lymphatic vessels. Targeting 
cells of the tumor medium prevents them of helping tumor growth, promoting an 
indirect death of tumor cells. Although this approach seems less effective for not 
directly attacking malignant cells, the access to the addresses is simpler since the 
peptide conjugated to the anti-tumor drug only has to reach the highly porous blood 
vessels of the tumor. In this regard, peptides with the ability to target tumor blood 
vessels show more targeting effects, reflecting a large number of studies. Furthermore, 
RGD and NGR peptides can be found in a wide number of clinical trials, which makes 
them the most suitable to integrate the first peptide-drug conjugate approved for clinical 
use. 
Among peptides targeting tumor vasculature, RGD and NGR are those that 
present all the key-points of information clear and developed. Today, researchers are 
guiding their research to the development of new iRGD analogues and NGR double-
targeting applications when converted to isoDGR. Regarding the others analyzed 
peptides in this targeting subtype, F3 contains exceptional internalizing properties and 
octreotide already has an optimized structure with excellent antagonistic capacity. 
However, both peptides require applicability studies in therapeutic conjugates. 
Both lymphatic vessels and other elements of tumor microenvironment are still 
poorly understood due to the lack of available information about this subject, which has 
limited the development of PDCs with these peptides. Studies have not yet revealed 
that targeting the tumor microenvironment is enough to effectively eliminate cancer 
cells, whereby they are only considered as adjuvant therapy. This way, LyP-1 is a good 
candidate as adjuvant treatment of metastases. On the other hand, CREKA and M2pep 
are known to bind to specific elements of the tumor microenvironment, but their 
addresses are unknown, which makes difficult the increment of new binding 
optimization studies. 
Although peptides homing tumor cells have more obstacles until reach their 
target, they may give additional features to PDCs. Angiopep 2 is able to cross the BBB, 
in addition to targeting brain tumors, which can offer significant therapeutic 
improvements over currently available treatments. Moreover, bombesin presents 
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antagonistic properties capable of duplicating the cytotoxic effect when integrating drug 
conjugates. 
The potential utilization of tumor targeting peptides can be extended to the 
treatment of others diseases, since angiogenesis is not exclusive of cancer, occurring 
in others medical conditions like arthritis and retinopathy. Furthermore, there are others 
pathological clotting activity regions, where CREKA can act, and several chronic 




















In this work, nine peptides showed a significant contribution for the scientific 
advances in the development of new anti-tumor conjugates with targeting ability that 
may become a common reality in clinical practice: RGD, NGR, F3, Octreotide, LyP-1, 
Bombesin, Angiopep 2, CREKA and M2pep (Table 3). However, it is necessary to 
invest in continuous research, especially in vivo studies, to improve the specificity, 
safety, efficiency and to adequate the structural modifications of these peptides and 
the respective drug conjugates.  
It is predictable that TTPs will reach significant clinical success and gradually 
evolve since, unlike Abs, the costs of production will not create a limitation to the use of 
this type of tumor therapy approach. In the near future, cancer patients will have 
access to more effective and less expensive tumor targeting therapies. Peptides-
targeted drug conjugates will allow the development of more personalized tumor 
treatments, increasing the quality of patients’ life.  
Table 3: TTPs reviewed in this work. 
Target Name Receptor Sequence 
Tumor Vasculature 








Octreotide Somatostatin f-c(CFwKTCT-ol) 
Tumor Lymphatic 
Vessels 
LyP-1 P32 CGNKRTRGC 
Tumor Cells 
Bombesin Bombesin H-pEQRLGNQWAVGHLM-NH2 
Angiopep 2 LRP-1 TFFYGGSRGKRNNFKTEEY 
Tumor 
Microenvironment 
CREKA Not determined CREKA 
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8 - Annexes 
Annex 1: Tumor Targeting Peptides 




Sequence Name Receptor Target cell 
Examples of peptide-drug 
and imaging probe 
conjugates 
CDCRGDCFC RGD-4C αvβ3/αvβ5 integrins 
Angiogenic blood 
vasculature 
Conjugated to DOX, PTX, 





CRGDKGPDC iRGD αvβ3/αvβ5 integrins 
Blood vessels and tumor 
cells 







F3 Nucleolin - 
DITWDQLWDLMK Esbp E-selectin Activated endotelial cells 
99m
Tc-Esbp 
WHSDMEWWYLLG F56 VEGFR-1 
Angiogenic blood 
vasculature, stromal cells, 














Angiogenic blood vessels, 
breast, prostate, 
melanoma and other 
cancer cells 
 
CREKA CREKA  
Fibrin-fibronectin 
complexes deposited as a 
result of subtle clotting 
CREKA-coated SPIONs 
and liposomes 
CTPSPFSHC TCP-1  












CKAAKNK KAA  Pancreatic tumor cells  
CRSRKG RSR  Angiogenic islet vessels  
CRGRRST RGR  
Angiogenic and 
premalignant, as well as 
tumorogenic blood vessels 
 
CGNKRTRGC LyP-1 P32 
Tumor cells, lymphatic 
endothelium, hypoxic areas 
inside tumor cells 
Conjugated to 
fluorochromes 
CNRRTKAGC LyP-2  Lymphatic vessels 
IFLLWQR IF7 Annexin 1   
CGLLIIQNEC CTL1 
 Clotted plasma proteins 
 
CNAGESSKNC CTL2  
CRRHWGFEFC 
 MMP-2/9 ECM  
CTTHWGFTLC 
CPGPEGAGC PEGA  Tumor blood vessels  








IAGEDGDEFG   
Proteases in breast cancer 
cells 
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YEQDPWGVKWWY M2pep  M2-like TAMs  
FYPSYHSTPQRP DC3  
DCs 
 
VTLTYEFAAGPRD P-D2 CD11c/CD18  
LSLERFLRCWSDAPA PP1 SR-A Macrophages  
Table 5: Peptides targeting tumor cells. Adapted.
7,11,12,14,32,41
 




WHSDMEWWYLLG F56 VEGFR-1 




LTVSPWY  Her2 
SWELYYPLRANL  E- and N-cadherins 
YCAREPPTRTFAYWG EPPT1 uMUC-1 
WHPWSYLWTQQA RP-1 CD44 
RLVSYNGIIFFLK A5G27 CD44v3 and CD44v6 
VLWLKNR FP16 FGF3 
CTVALPGGYVRVC pep42 GRP78 
c-dGHCitGPQ-c OA02 Alpha 3-integrin 
TAASGVRSMH TAA 


















Glp-GPWLEEEEEAYGWMDF-NH2 Gastrin Gastrin 




CPRECESIC  Aminopeptidase A 
GTRIIYDRKFLMECRNSPVT  GnRH 
CRKRLDRN  IL-4 
KCCYSL  ErbB-2 
EDYELMDLLAYLK  
Somatostatin FCYWKTCT  
H-AGCKNFFWKTFTSC-OH Somatostatin 




Cholecystokinin-B/ Gastrin receptor 
 DYMGWMDF-NH2 CCK-8 
GWMDF-NH2 Gastrin 
GNLWATGHFM-NH2 Neuromedin B NMBR 
EWPRPQIPP- NH2 BPP Bradykinin Receptor B2 
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Annex 2: Tumor Targeting Peptides-based Nanomedicines 






RGD Doxo-liposomes (RGD-LCL) 
pHPMA-RGDfKDTX and pHPMARGD4C 
PGA-PTX-E-[c(RGDfK)2] 
RGD-G3-poly(Llysine)-dendrimer[DOX]/siRNA complexes 
RGD-lipopeptide 1/p53 plasmid 
cRGDfK-PEG-PCL micelles loaded with DOX and SPIO 
cRGD decorated nanoparticles or micelles (constructed from PEG-PLGA, PEG-PCL, 
PEGPTMC, PEG-PGA, POE-PCL, PEG-PLA) 
NGR Liposomes (TVTDOX) 
Nanoparticles (NGRPEG-PLGA(DTX)) 
NGR-modified (DTX)-loaded PEG-b-PLA polymeric micelles (NGR-PMDTX) NGR-modified 
DSPE-PEG micelles (NGR-M-PTX) 
Polymer-drug conjugates (pHPMA-(NGR)-D(KLAKLAK)2) 






analog of sLex 
Polymer conjugate (pHPMA-Qa-FITC) 
Esbp Polymer-drug conjugates (pHPMA-(Esbp)-DOX, pHPMA-(Esbp)-KLAK 







GE11-PEG-PEI polyinosine/cytosine (polyIC) polyplexes 
G3-C12 pHPMA-(G3-C12)- FITC 
G3-C12-HPMA– DOX 




Polymeric micelles (DOX-AP-pH-PM) 
P-D2 P-D2-decorated PLGA 
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Annex 3: RGD and NGR Peptides under Clinic Evaluation   
Table 7: RGR peptides under clinic evaluation. Taken from 
13
 
Condition Status Intervention Phase Year 
Glioblastoma Ongoing Single intratumoral injection of Delta-24-
RGD; Interferon-gamma 
I 2014 
Glioblastoma Ongoing 18F-Galacto-RGD PET I 2013 
Glioblastoma; Multiforme; Recurrent Tumor Ongoing Delta-24-RGD Temozolomide I 2013 
Prostate Cancer Recruiting 68Ga-NOTA-BBN-RGD I 2016 
Breast Cancer Recruiting 68Ga-NOTA-BBN-RGD I 2016 
Lung Cancer Recruiting 68Ga-NOTA-3PTATE-RGD I 2016 
Pathological Angiogenesis Recruiting 68Ga-NODAGA-RGD PET/CT I 2016 
Brain Cancer; Brain Neoplasm; etc Recruiting Delta-24-RGD II 2016 
Diffuse Large B Cell Lymphoma Recruiting RGD K5 PET scan II 2015 
Bronchogenic Carcinoma; Breast 
Carcinoma; etc 
Recruiting 18F-Al-NOTA-PRGD2 PET/CT I 2015 
Advanced Head and Neck Carcinoma 
Advanced Non-small Cell Lung Carcinoma 
Recruiting Radiopharmaceutical (Flotegatide (18F) 
or RGD (68Ga) 
II 2014 
Non-seminomatous Germ Cell Tumors 
Metastasis 
Recruiting K5-RGD PET II 2014 
Solid tumors Recruiting 18F FPPRGD2 PET/CT I&II 2013 
Lung Cancer; Lung Tuberculosis Completed 68Ga-labeled peptides of dimer RGD I&II 2015 
Breast Cancer Completed Breast Cancer  2010 
Brain Tumor; Recurring Glioblastoma Completed Delta-24-RGD adenovirus I&II 2010 
Metastatic Breast Cancer; Metastatic 
Colon/Rectum Cancer; etc 
Completed [F-18]RGD-K5 II 2009 
Ovarian Cancer Completed Ad5.SSTR/TK-RGD; Ganciclovir (GCV) I 2009 
Sarcoma; Melanoma; etc Completed F-18 RGD-K5 I 2008 
Brain Cancer Completed Delta-24-RGD-4C I 2008 
Ovarian Cancer Completed Ad5-delta24RGD I 2007 
High-grade Glioma; Lung Cancer; etc Completed Fluciclatide Injection - (AH111585 
(F18)) 
II 2007 
Kidney Neoplasm Terminated 18F-Fluciclatide containing the RGD II 2013 
Carcinoma, Renal Cell Unknown 18F-RGD-PET-CT and perfusion CT 
scans on 3 occasions 
II 2011 
Head and Neck Neoplasms Unknown [18F]RGD-K5 II 2011 
Glioma Unknown 68Ga-BNOTA-PRGD2  I 2013 
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Table 8: NGR peptides under clinic evaluation. Taken from 
13
 
Condition Status Intervention Phase Year 
Solid tumors Ongoing NGR-hTNFα I 2007 
Small cell lung cancer Ongoing 
NGR-hTNF: iv q3W 0.8 mcg/sqm NGR-hTNF; Doxorubicin: 
iv q3W 75 mg/sqm doxorubicin 60 min after NGR-hTNF 
infusion 
II 2007 
Ovarian cancer Ongoing 
NGR-hTNFα; Pegylated liposomal-doxorubicin; 
Doxorubicin 
II 2011 
Ovarian cancer Ongoing 
NGR-hTNF: 0.8 mcg/m
2
 as 60-min intravenous infusion 
every week until confirmed evidence of disease 
progression or unacceptable toxicity occurs; Doxorubicin: 
60 mg/m
2





Non-small cell lung 
cancer 
Ongoing NGR-hTNFα; Cisplatin; Gemcitabine; Pemetrexed II 2010 
Soft-tissue sarcoma Ongoing NGR-hTNFα; Doxorubicin II 2007 
Malignant pleural 
mesothelioma 
Ongoing NGR-hTNFα plus best investigator choice III 2009 
Malignant pleural 
mesothelioma 
Recruiting NGR-hTNFα II 2007 






Solid tumors Completed 
NGR-hTNF:iv q3W escalating dose NGR-hTNF up to 1.6 
mcg/sqm; Cisplatin: iv q3W 80 mg/sqm 30 min after NGR-






Solid tumors Completed 
NGR-hTNF: 0.2, 0.4, 0.8 and 1.6 mg/m2as 60-min 
intravenous infusion every 3 weeks; Doxorubicin: 75 
mg/m
2
 intravenous infusion over 15 min (starting 1 h after 







Head and Neck Cancer, 
etc 
Completed CNGRC peptide-TNF alpha conjugate I 2006 
Colorectal cancer Completed NGR-hTNFα: iv q3W or q1W NGR-hTNF 0.8 mg/m
2
 II 2009 
Colorectal cancer Completed NGR-hTNFα; Oxaliplatin; Capecitabine II 2008 
Malignant pleural 
mesothelioma 
Completed NGR-hTNFα: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF II 2004 
Hepatocellular 
carcinoma 
Completed NGR-hTNFα: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF II 2007 
 
 
 
